Search results
Showing 676 to 690 of 985 results for drug therapy
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)
NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)
NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
lack of evidence makes it difficult to optimise initial therapy, either by specifying specific drugs within the class or...
who have had unsuccessful first surgery, and very limited evidence on drug therapy with cinacalcet compared with placebo. The committee...
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .